Invivyd stock falls 8 percent as earnings miss estimates

Published on 09/23/2026 at 01:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Invivyd stock fell 8 percent on September 22, 2026, while six analysts kept a Hold consensus. Quarterly revenue reached USD 14.29 million, below estimates.

IVVD, US46186M1080, Illustration mit AI erstellt.

Invivyd stock (ISIN US46186M1080) fell 8 percent on September 22, 2026, according to Polygon data cited by Quiver Quant, with trading volume of approximately USD 1,536,818. The move leaves the biotechnology company balancing a USD 300.66 million market capitalization against a recent quarterly earnings shortfall.

Quarterly revenue misses estimates

According to MarketBeat on September 22, 2026, Invivyd reported fiscal second-quarter EPS of negative USD 0.14, missing the consensus estimate of negative USD 0.11 by USD 0.03. Revenue for the quarter was USD 14.29 million, compared with an estimate of USD 14.40 million.

The comparison is narrow on revenue but more pronounced on earnings: the USD 0.03 EPS miss amounted to roughly 27 percent of the expected loss per share. MarketBeat also reported a negative net margin of 183.90 percent for the same quarter, underscoring how operating costs continue to outweigh sales.

Hold consensus and narrow range

Six analysts covering Invivyd carried a consensus recommendation of Hold as of September 22, 2026, according to MarketBeat. The average twelve-month price objective was USD 8.00, a figure that provides a clear reference point for the current market valuation but is not a company forecast.

The same September 22, 2026 market overview placed the shares between a one-year low of USD 0.53 and a one-year high of USD 3.07. That range matters because the stock's market capitalization and price remain highly sensitive to changes in clinical, commercial and financing expectations.

Stock closes near a low valuation

Invivyd opened at USD 1.02 on Nasdaq on September 22, 2026, while the reported market capitalization stood at USD 300.66 million and the price-to-earnings ratio was negative 3.09. The dated price reaction and the negative EPS result point to earnings execution as the immediate numerical counterweight to the analyst consensus.

For investors, the key figures are therefore the USD 14.29 million quarterly revenue, the negative USD 0.14 EPS and the USD 8.00 average analyst objective. Each belongs to a different measurement: operating sales, quarterly profitability and twelve-month valuation expectations.

Nasdaq level remains below yearly high

Invivyd stock was quoted at USD 1.02 on Nasdaq on September 22, 2026. The same date's one-year range of USD 0.53 to USD 3.07 places the quoted level USD 2.05 below the high and USD 0.49 above the low.